Sector Gamma As
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 8, 2024), Sector Gamma As reported 28 stock positions worth $354.8 million. Its top holding was Medtronic (MDT) at 10.1% of the portfolio, followed by Pfizer (PFE, 9.7%) and Bristol-Myers Squibb (BMY, 7.6%). Compared with Q4 2023, it opened 3 new positions, sold out of 5, added to 9 and reduced 16. The biggest buy was a new position in Universal Health Services-B (UHS) and the biggest sale Centene (CNC, shares −90%).
- Most Recent 13F
- Q2 2026
- Location
- OSLO, Q8
- CIK
- 0001475373
- Portfolio Value
- $354.8M (Q1 2024)
- SEC Filing
- 0000945621-24-000393 ↗ filed May 8, 2024
Holdings Value
Holdings 28 stocks · $354.8M
| MDT Medtronic PLC | 10.12% | 411,893 | $35.9M | Reduce -5.3% |
| PFE Pfizer Inc. | 9.69% | 1,239,165 | $34.4M | Add +13.3% |
| BMY Bristol-Myers Squibb Co. | 7.62% | 498,536 | $27.0M | Add +33.0% |
| CVS CVS Health Corp. | 6.92% | 308,004 | $24.6M | Add +40.6% |
| CAH Cardinal Health Inc. | 5.76% | 182,587 | $20.4M | Add +11.1% |
| GILD Gilead Sciences Inc. | 5.48% | 265,619 | $19.5M | Reduce -30.5% |
| ELV Elevance Health Inc. | 5.01% | 34,297 | $17.8M | Add +23.3% |
| ZBH Zimmer Biomet Holdings Inc. | 4.50% | 121,033 | $16.0M | Reduce -14.3% |
| INCY Incyte Corp. | 4.25% | 264,895 | $15.1M | Reduce -33.6% |
| BAX Baxter International Inc. | 3.89% | 323,120 | $13.8M | Reduce -1.5% |
| BIIB Biogen Inc. | 3.63% | 59,698 | $12.9M | Reduce -41.6% |
| UHS Universal Health Services-B | 3.59% | 69,881 | $12.8M | New |
| BIO Bio-Rad Laboratories-A | 3.28% | 33,662 | $11.6M | Add +42.6% |
| GEHC GE Healthcare Technology | 3.16% | 123,133 | $11.2M | Reduce -50.3% |
| BRKR Bruker Corp. | 2.99% | 112,775 | $10.6M | Reduce -11.4% |
| EW Edwards Lifesciences Corp. | 2.88% | 106,866 | $10.2M | Reduce -43.0% |
| THC Tenet Healthcare Corp. | 2.30% | 77,535 | $8.1M | Reduce -59.9% |
| IONS Ionis Pharmaceuticals Inc. | 2.14% | 175,507 | $7.6M | Add +21.0% |
| BMRN Biomarin Pharmaceutical Inc. | 2.00% | 81,416 | $7.1M | Reduce -5.6% |
| ALKS Alkermes PLC | 1.93% | 252,319 | $6.8M | Add +26.2% |
| GMED Globus Medical Inc. Class A | 1.59% | 105,381 | $5.7M | Reduce -55.0% |
| VTRS Viatris Inc. | 1.41% | 417,657 | $5.0M | New |
| AGIO Agios Pharmaceuticals Inc. | 1.35% | 164,378 | $4.8M | New |
| QGEN Qiagen NV | 1.25% | 103,369 | $4.4M | Reduce -44.1% |
| ALNY Alnylam Pharmaceuticals Inc. | 1.16% | 27,583 | $4.1M | Reduce -14.1% |
| LNTH Lantheus Holdings Inc. | 0.93% | 53,060 | $3.3M | Add +1.4% |
| ILMN Illumina Inc. | 0.66% | 17,000 | $2.3M | Reduce -58.1% |
| CNC Centene Corp. | 0.49% | 22,216 | $1.7M | Reduce -89.7% |
Portfolio Sells Q4 2023 → Q1 2024
| CNC Centene Corp. | Reduce -89.7% | 0.49% | −3.41 |
| LH Laboratory CRP of Amer Hldgs | Sold out | 0.00% | −2.80 |
| BIIB Biogen Inc. | Reduce -41.6% | 3.63% | −2.79 |
| GILD Gilead Sciences Inc. | Reduce -30.5% | 5.48% | −2.03 |
| INCY Incyte Corp. | Reduce -33.6% | 4.25% | −1.82 |
| GEHC GE Healthcare Technology | Reduce -50.3% | 3.16% | −1.49 |
| GMED Globus Medical Inc. Class A | Reduce -55.0% | 1.59% | −1.44 |
| ACAD Acadia Pharmaceuticals Inc. | Sold out | 0.00% | −1.43 |
| THC Tenet Healthcare Corp. | Reduce -59.9% | 2.30% | −1.25 |
| RARE Ultragenyx Pharmaceutical Inc. | Sold out | 0.00% | −1.19 |
| ABT Abbott Laboratories | Sold out | 0.00% | −1.06 |
| QGEN Qiagen NV | Reduce -44.1% | 1.25% | −0.76 |
| ILMN Illumina Inc. | Reduce -58.1% | 0.66% | −0.71 |
| EW Edwards Lifesciences Corp. | Reduce -43.0% | 2.88% | −0.59 |
| VIR Vir Biotechnology Inc. | Sold out | 0.00% | −0.36 |
| ALNY Alnylam Pharmaceuticals Inc. | Reduce -14.1% | 1.16% | −0.33 |
| BMRN Biomarin Pharmaceutical Inc. | Reduce -5.6% | 2.00% | −0.01 |
| ZBH Zimmer Biomet Holdings Inc. | Reduce -14.3% | 4.50% | +0.33 |
| BRKR Bruker Corp. | Reduce -11.4% | 2.99% | +0.72 |
| BAX Baxter International Inc. | Reduce -1.5% | 3.89% | +0.81 |
| MDT Medtronic PLC | Reduce -5.3% | 10.12% | +1.42 |
Portfolio Buys Q4 2023 → Q1 2024
| UHS Universal Health Services-B | New | 3.59% | +3.59 |
| BMY Bristol-Myers Squibb Co. | Add +33.0% | 7.62% | +2.96 |
| CVS CVS Health Corp. | Add +40.6% | 6.92% | +2.73 |
| PFE Pfizer Inc. | Add +13.3% | 9.69% | +2.05 |
| ELV Elevance Health Inc. | Add +23.3% | 5.01% | +1.83 |
| CAH Cardinal Health Inc. | Add +11.1% | 5.76% | +1.74 |
| BIO Bio-Rad Laboratories-A | Add +42.6% | 3.28% | +1.43 |
| VTRS Viatris Inc. | New | 1.41% | +1.41 |
| AGIO Agios Pharmaceuticals Inc. | New | 1.35% | +1.35 |
| ALKS Alkermes PLC | Add +26.2% | 1.93% | +0.58 |
| IONS Ionis Pharmaceuticals Inc. | Add +21.0% | 2.14% | +0.36 |
| LNTH Lantheus Holdings Inc. | Add +1.4% | 0.93% | +0.14 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 40 | $461.0M | BMY, MRK, MDT, PFE, INCY |
| Q1 2026 | 42 | $423.5M | BMY, MRK, PFE, MDT, INCY |
| Q4 2025 | 36 | $438.7M | BMY, MRK, MDT, BDX, GILD |
| Q3 2025 | 41 | $403.3M | PFE, MDT, MRK, BMY, BDX |
| Q2 2025 | 38 | $305.9M | PFE, MDT, BMY, BDX, MRK |
| Q1 2025 | 33 | $312.2M | BMY, PFE, BDX, MDT, AMGN |
| Q4 2024 | 30 | $290.9M | PFE, MDT, BMY, GILD, BDX |
| Q3 2024 | 29 | $329.6M | BMY, MDT, GILD, PFE, CVS |
| Q2 2024 | 28 | $267.7M | GILD, PFE, BMY, MDT, ELV |
| Q1 2024 | 28 | $354.8M | MDT, PFE, BMY, CVS, CAH |